Michael J. Kluk, MD, PhD

Assistant Professor
Department of Pathology and Laboratory Medicine
Director of Molecular and Genomic Pathology
Weill Cornell Medical College
New York Presbyterian Hospital
New York, NY 10065, USA


Dr. Kluk completed MD, PhD training at University of Connecticut School of Medicine, residency training in Anatomic Pathology and Laboratory Medicine (Yale School of Medicine) and Fellowship training in Hematopathology (Massachusetts General Hospital) and in Molecular Pathology (Brigham and Women’s Hospital, BWH). He also performed Post-doctoral research in the Department of Pathology at Brigham and Women’s Hospital where he worked in translational research investigating the use of new biomarkers in a variety of diseases including sphingosine-1-phosphate receptor-1 (S1PR1) in classic Hodgkin lymphoma (CHL). In addition, while at BWH, he studied the role of MYC in diffuse large B cell lymphoma (DLBCL). This work included correlation of MYC IHC with molecular expression profile results. After publication, the MYC staining method was transitioned for use in the routine diagnostic work up of clinical cases. Most recently, he worked with others to develop an IHC staining method to gauge NOTCH1 activation in formalin fixed paraffin embedded tissue sections and has compared the NOTCH-1 activation status results to NOTCH1 mutation status. This work has also been published.
In addition to these projects, he was also extensively involved in a clinical trial directed by the TIMI Study Group (BWH) which was done in collaboration with the Center for Advanced Molecular Diagnostics (CAMD) to develop and validate a pyrosequencing assay used to assess CYP2c19*2 status in the clinical samples. Also, while at BWH, he helped to implement an amplification-based next generation sequencing test to assess mutation status in over 90 genes of clinical significance in myeloid and lymphoid diseases and he worked as one of the pathologists involved in the review of next generation sequencing data generated as part of PROFILE, the BWH/DFCI collaborative clinical research initiative.
Currently, he is a Director of Molecular and Genomic Pathology at Weill Cornell Medical College/New York Presbyterian Hospital.

Research Interest

His research interests include: Diagnostic Molecular Pathology and Hematopathology, including a focus on the development of new tools that can be used in the diagnostic workup of clinical specimens and in translational research.

Scientific Activities


• (1995-1996) Rennes Exchange Teaching Fellowship University of Rochester
• (2001) Trainee Travel Award American Society Clinical Investigation
• (2009) Clinical Research Day Poster Award Massachusetts General Hospital
• (2011) Clinical Research Day Poster Award Beth Israel Deaconess Medical Center
• (2012) Stanley Robbins Memorial Research Award Brigham and Women’s Hospital
• (2012) Eleanor and Miles Shore Research Fellowship Brigham and Women’s Hospital



1. Lee MJ, Thangada S, Claffey KP, et al. Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate. Cell. 1999; 99: 301-312. doi: 10.1016/S0092-8674(00)81661-X
2. Kluk MJ, Hla T. Role of the Sphingosine-1-Phosphate Receptor EDG-1 in Vascular Smooth Muscle Cell Proliferation and Migration. Circ. Res. 2001; 89: 496-502. doi: 10.1161/hh1801.096338
3. Kluk MJ, Colmont C, Wu M, Hla T. Platelet-derived Growth Factor (PDGF)-induced Chemotaxis Does Not Require the G Protein Coupled Receptor S1P1 in Murine Embryonic Fibroblasts and Vascular Smooth Muscle Cells. FEBS Letters. 2003; 533: 25-28. doi: .1016/S0014-5793(02)03742-0
4. Ray CM, Kluk M, Grin CM, Grant-Kels JM. Successful Treatment of Malignant Melanoma in situ with Topical 5% Imiquimod Cream. Int. J. Dermatol. 2005; 44(5): 428-434. doi: 10.1111/j.1365-4632.2005.02582.x
5. Dotto J, Kluk M, Geramizadeh B, Tavassoli FA. Frequency of Clinically Occult Intraepithelial and Invasive NEoplasia in Reduction Mammoplasty Specimens: A Study of 516 Cases. Int. J. Surg. Pathol. 2008; 16(1): 25-30. doi: 10.1177/1066896907307176
6. Cannizzo E, Sohani AR, Ferry JA, et al. Carcinoma and Multiple Lymphomas in One Patient: Establishing the Diagnoses and Analyzing Risk Factors. J. Hematop. 2009; 2(3): 163-170. doi: 10.1007/s12308-009-0041-0
7. Poitras JL, Costa D, Kluk MJ, et al. Genomic Alterations in Myeloid Neoplasms with Novel Apparently Balanced Translocations. Cancer Genet. 2011; 204(2): 68-76. doi: 10.1016/j.cancergen.2010.12.005.
8. Kluk MJ, An Y, James P, et al. Avoiding Pitfalls in Molecular Genetic Testing: Case Studies of High Resolution Array CGH Testing in the Definitive Diagnosis of Mowat-Wilson Syndrome. J. Molec. Diag. 2011; 13(3): 363-367. doi: g/10.1016/j.jmoldx.2011.01.008
9. Wang X, Werneck MBF, Wilson BG, et al. T Cell Receptor Dependent Transformation of Mature Memory Phenotype T cells in Mice. J. Clin. Invest. 2011; 121(10): 3834-3845. doi: 10.1172/JCI37210
10. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA. 2011; 306(20): 2221-2228. doi: 10.1001/jama.2011.1703.
11. Nardi V, Winkfield KM, Ok CY, et al. Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Radiation Therapy Are Similar to De Novo Disease and Differ from other Therapy-related Myeloid Neoplasms. J. Clin. Oncol. 2012; 30(19): 2340-2347. doi: 10.1200/JCO.2011.38.7340
12. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas. PLoS One. 2012; 7(4): e33813. doi: 10.1371/journal.pone.0033813
13. Kluk M, Ryan K, Wang B, Zhang G, Rodig S, Sanchez T. Sphingosine-1-Phosphate Receptor 1 in Classical Hodgkin Lymphoma: Assessment of Expression and Role in Cell Migration. Lab. Invest. 2013; 93(4): 462-471. doi: 10.1038/labinvest.2013.7
14. Zhang G, Yang L, Kim G, et al. Critical Role of Sphingosine-1-Phosphate Receptor 2 (S1PR2) in Acute Vascular Inflammation. Blood. 2013; 122(3): 443-455. doi: 10.1182/blood-2012-11-467191
15. Kluk MJ, Ashworth T, Wang H, et al. Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One. 2013; 8(6): e67306. doi:
16. Grayson AR, Walsh EM, Cameron MJ, et al. MYC, a Downstream Target of BRD-NUT, is Necessary and Sufficient for the Blockade of Differentiation in NUT Midline Carcinoma. Oncogene. 2014; 33(13): 1736-1742. doi: 10.1038/onc.2013.126.
17. Xu L, Hunter ZR, Yang G, et al. Detection of MYD88 L265P in Peripheral Blood of Patients with Waldenströms Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Leukemia. 2014; 28(8): 1698-1704. doi: 10.1038/leu.2014.65.
18. Knoechel B, Roderick JE, Williamson KE, et al. An Epigenetic Mechanism of Resistance to Targeted Therapy in T Cell Acute Lymphoblastic Leukemia. Nat. Genet. 2014; 46(4): 364-370. doi: 10.1038/ng.2913
19. Gerhardt DM, Pajcini KV, Daltri T, et al. The NOTCH1 Transcriptional Activation Domain is Required for Development and Reveals a Novel Role for NOTCH1 Signaling in Fetal Hematopoietic Stem Cells. Genes Dev. 2014; 28(6): 576-593. doi: 10.1101/gad.227496.113
20. South AP, Purdie KJ, Watt SA, et al. NOTCH1 Mutations Occur Early During Cutaneous Squamous Cell Carcinogenesis. J. Invest. Dermatol. 2014; 134(10): 2630-2638. doi: 10.1038/jid.2014.154
21. Stoeck A, Lejnine S, Truong A, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov. 2014; 4(10): 1154-1167. doi: 10.1158/2159-8290.CD-13-0830.
22. MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J. Mol. Diagn. 2014; 16(6): 660-672. doi: 10.1016/j.jmoldx.2014.06.004
23. Li N, Fassl A, Chick J, et al. Cyclin C is a haploinsufficient tumour suppressor. Nat. Cell Biol. 2014; 16(11): 1080-1091. doi: 10.1038/ncb3046
24. Jaiswal S, Fontanillas P, Flannick J, et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N. Engl. J. Med. 2014. doi: 10.1056/NEJMoa1408617
25. Carey CD, Gusenleitner D, Chapuy B, et al. Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. J. Mol. Diagn. 2014; S1525-1578(14): 204-209.


1. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids: Receptor Revelations. Science. 2001; 294: 1875-1878. doi: 10.1126/science.1065323
2. Kluk MJ, Hla T. Signaling of Sphingosine-1-Phosphate via the S1P/EDG Family of G-Protein Coupled Receptors. Biochim. Biophys. Acta. 2002; 1582: 72-80. doi: 10.1016/S1388-1981(02)00139-7
3. Kluk MJ, Grant-Kels JM, Kerr P, et al. Melanoma on the move: The Progression of Melanoma. Novel Concepts with Histologic Correlates. Am. J. Dermatopathol. 2004; 26(6): 504-510.


1. Kluk MJ, Longtine JA. Chronic Myelogenous Leukemia. In: Schrijver I, Ed. Molecular Pathology in Practice. Philadelphia: Springer Publishing; 2010.